Tris Pharma (United States)
In research, Tris Pharma (United States) stands highest in Health Sciences (#9,645 of 11,982 worldwide), 2022–2025.
- World rank, 2022–2025
- #15,136 of 28,054 · #7,244 all time
- Rank in United States
- #2,138 of 4,192
- Research works
- 783 ▼ 17% vs 2013–17
- Citations
- 32k 40.5 per fractional work
- Top-10% rate
- 14.9% record average 16.5%
- Open access
- 40% world 28%
What is Tris Pharma (United States) known for in research?
The fields where it stands highest, 2022–2025, ranked among every institution above the floor in each field.
| Field | World rank | Where that sits | Top-10% rate | Works | All time |
|---|---|---|---|---|---|
| Health SciencesDomain | #9,645 of 11,982 | 17.2% | 62 | #3221 |
Each strip is that field’s whole ranked pool, with the notch where Tris Pharma (United States) sits in it, in the colour of the band that rank falls in. The track under the rate is the rate itself: it carries no world mark, because the world rate differs by field (from about 6% to 21% in this record).
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Mathematics, 3.6×. Every wedge is a field page.
- Mathematics 3.6×
- Pharmacology, Toxicology and Pharmaceutics 3.4×
- Immunology and Microbiology 3.1×
- Medicine 2.3×
- Veterinary 1.9×
- Biochemistry, Genetics and Molecular Biology 1.8×
- Health Professions 1.4×
- Neuroscience 1.4×
- Economics, Econometrics and Finance 1.4×
- Physics and Astronomy 1.2×
- Psychology 1.1×
- Decision Sciences 1.0×
- Chemistry 0.7×
- Arts and Humanities 0.6×
- Dentistry 0.5×
- Materials Science 0.5×
- Engineering 0.4×
- Computer Science 0.3×
- Business, Management and Accounting 0.3×
- Agricultural and Biological Sciences 0.3×
- Social Sciences 0.3×
- Environmental Science 0.2×
- Earth and Planetary Sciences 0.2×
Which keywords describe research at Tris Pharma (United States)?
By fractional works in 2022–2025, weighted toward what it does more of than the world: Genetics, Epidemiology, Treatment, Quality of Life, Inflammation, Clinical Trials, Cancer and Bayesian Methods.
- Immune
- Genomic Profiling
- Material Differentiation
- Health Utility Measures
- Cost-effectiveness Analysis
- Adaptive Designs
- Ptychography
- Cognitive Impairment
- Autoantibodies
- Tomography
- Heart Failure
- Brain Imaging
- Targeted Therapy
- Bayesian Methods
- Regulation
- Depression
- Clinical Trials
- Cancer
- Treatment
- Inflammation
- Epidemiology
- Quality of Life
- Genetics
- Cardiovascular Disease
- Biomarkers
- Diagnosis
- Genetic Mutations
- Immunotherapy
- Neurobiology
- Prevalence
- Meta-Analysis
- Comorbidity
- X-ray Imaging
- Phase Retrieval
- ADHD
- Attention-Deficit/Hyperactivity Disorder
- False Discovery Rate
- Dual-Energy CT
- Inflammatory Diseases
- Complement
Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 40 words, with their numbers
- Epidemiology9▲ 1.79×51 topics
- Inflammation6▲ 2.4×39 topics
- Quality of Life6▲ 3.3×17 topics
- Treatment6▲ 3.8×23 topics
- Genetics5▲ 6.0×11 topics
- Cancer5▲ 2.9×24 topics
- Cardiovascular Disease4▲ 3.0×19 topics
- Clinical Trials4▲ 4.6×11 topics
- Biomarkers4▲ 4.2×11 topics
- Depression3▲ 3.1×11 topics
- Diagnosis3▲ 2.8×16 topics
- Regulation3▲ 4.9×5 topics
- Genetic Mutations3▲ 5.3×15 topics
- Bayesian Methods3▲ 44×2 topics
- Immunotherapy3▲ 3.0×14 topics
- Targeted Therapy3▲ 9.5×5 topics
- Neurobiology3▲ 7.8×6 topics
- Brain Imaging2▲ 25×2 topics
- Prevalence2▲ 4.8×5 topics
- Heart Failure2▲ 4.4×12 topics
- Meta-Analysis2▲ 3.2×4 topics
- Tomography2▲ 10×3 topics
- Comorbidity2▲ 16×2 topics
- Autoantibodies2▲ 7.2×7 topics
- X-ray Imaging2▲ 49×2 topics
- Cognitive Impairment2▲ 6.5×5 topics
- Phase Retrieval2▲ 111×1 topic
- Ptychography2▲ 111×1 topic
- ADHD2▲ 42×1 topic
- Adaptive Designs2▲ 76×1 topic
- Attention-Deficit/Hyperactivity Disorder2▲ 42×1 topic
- Cost-effectiveness Analysis2▲ 18×1 topic
- False Discovery Rate2▲ 76×1 topic
- Health Utility Measures2▲ 18×1 topic
- Dual-Energy CT2▲ 35×1 topic
- Material Differentiation2▲ 35×1 topic
- Inflammatory Diseases2▲ 7.9×3 topics
- Genomic Profiling2▲ 13×2 topics
- Complement2▲ 74×1 topic
- Immune2▲ 74×1 topic
Which research topics does Tris Pharma (United States) publish most on?
By volume in 2022–2025: Advanced X-ray Imaging Techniques, Health Systems, Economic Evaluations, Quality of Life, Attention Deficit Hyperactivity Disorder and Statistical Methods in Clinical Trials.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Advanced X-ray Imaging Techniques Radiation 2 works
- 2 Health Systems, Economic Evaluations, Quality of Life Economics and Econometrics 2 works
- 3 Attention Deficit Hyperactivity Disorder Psychiatry and Mental health 2 works
- 4 Statistical Methods in Clinical Trials Statistics and Probability 2 works
- 5 Advanced X-ray and CT Imaging Biomedical Engineering 2 works
- 6 Complement system in diseases Immunology 2 works
- 7 Renal Diseases and Glomerulopathies Nephrology 2 works
- 8 Sexual function and dysfunction studies Psychiatry and Mental health 1 works
- 9 Lung Cancer Treatments and Mutations Pulmonary and Respiratory Medicine 1 works
- 10 Statistical Methods and Bayesian Inference Statistics and Probability 1 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Tris Pharma (United States)'s research output changed?
Output in 2018–2022 was 17% lower than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Monmouth Junction
- United Silicon Carbide (United States)
- Knite (United States)
- Provid Pharmaceuticals (United States)
- PharmaSeq (United States)
- CytoSorbents (United States)
- Nanonex (United States)
- Diamir (United States)
- Xeme Biopharma (United States)
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.